Moxifloxacin: Broad-Spectrum DNA Gyrase Inhibitor for Antibacterial and Cellular Research

Executive Summary: Moxifloxacin (CAS 151096-09-2) is a broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, disrupting DNA replication and transcription (Gibson et al., 2019). The compound displays robust antibacterial activity against Gram-positive and Gram-negative pathogens. In research settings, Moxifloxacin induces dose-dependent cytotoxicity and reduces proliferation of RGC5 retinal ganglion cells at concentrations above 50 μg/mL. In vivo, intravenous administration at 100 mg/kg in male Wistar rats elevates serum glucose, adrenaline, and histamine, revealing metabolic and immunological effects. APExBIO provides validated, high-purity Moxifloxacin (SKU B1218) for advanced cellular, toxicity, and metabolic studies (product page).

Biological Rationale

Moxifloxacin, a fourth-generation fluoroquinolone, targets bacterial DNA gyrase and topoisomerase IV. These enzymes are essential for bacterial DNA topology, replication, and survival (Gibson et al., 2019). DNA gyrase introduces negative supercoils into DNA, a process critical for counteracting torsional stress during replication and transcription. By inhibiting these enzymes, Moxifloxacin suppresses bacterial propagation and is widely used in research on antibiotic mechanisms, resistance, and toxicity. Its broad-spectrum efficacy is relevant for studying Gram-positive and Gram-negative bacterial models.

Mechanism of Action of Moxifloxacin

Moxifloxacin binds to the DNA–gyrase complex, stabilizing the enzyme-DNA cleavage intermediate. This action results in double-stranded breaks in bacterial DNA, preventing religation and ultimately leading to cell death (DOI). Unlike gepotidacin, which induces only single-stranded breaks, Moxifloxacin is characterized by its double-stranded cleavage activity. The inhibitory effect is concentration-dependent and selective for prokaryotic gyrase and topoisomerase IV, with minimal activity against eukaryotic topoisomerases at research-relevant doses. The molecular formula for Moxifloxacin is C21H24FN3O4, and its molecular weight is 401.43. The compound dissolves at ≥25.6 mg/mL in water and ≥50.8 mg/mL in DMSO under gentle warming and sonication.

Evidence & Benchmarks

• Moxifloxacin inhibits bacterial DNA gyrase, resulting in loss of DNA supercoiling and bacterial cell death (Gibson et al., 2019).
• APExBIO Moxifloxacin (SKU B1218) is a solid compound with validated solubility: ≥25.6 mg/mL in water and ≥50.8 mg/mL in DMSO at 20–25°C with sonication (product).
• Moxifloxacin induces significant dose-dependent antiproliferative and cytotoxic effects on rat retinal ganglion cells (RGC5) above 50 μg/mL in vitro (protocol guide).
• In male Wistar rats, intravenous Moxifloxacin at 100 mg/kg (but not 75 mg/kg) raises serum glucose, adrenaline, and histamine, indicating metabolic and immune pathway activation (APExBIO).
• DNA gyrase inhibition by fluoroquinolones is blocked by specific target mutations, a major resistance mechanism in clinical isolates (Gibson et al., 2019).

Applications, Limits & Misconceptions

Moxifloxacin is used in research to study:

• Antibacterial efficacy and resistance mechanisms via DNA gyrase inhibition.
• Cell viability, cytotoxicity, and proliferation in mammalian cell models (detailed assay guide). This article extends prior guidance by providing metabolic and immunological evidence from animal models.
• Metabolic regulation and histamine-mediated immunological pathways in rodents.
• Exploration of antibiotic toxicity and cellular stress responses (cell viability workflow). Here, new data on in vivo metabolic markers are summarized for translational insight.

Common Pitfalls or Misconceptions

• Moxifloxacin is not effective against bacteria with gyrase or topoisomerase IV mutations conferring fluoroquinolone resistance.
• The compound is not selective for eukaryotic topoisomerases and should not be used as an exclusive eukaryotic DNA synthesis inhibitor.
• Observed metabolic effects (e.g., hyperglycemia, histamine release) are dose-specific and not generalizable to all concentrations or species.
• Solubility is temperature and solvent dependent; improper preparation may lead to suboptimal assay performance.
• Moxifloxacin's cytotoxicity in mammalian cells is significant only at concentrations above 50 μg/mL; lower concentrations may not yield observable effects.

Workflow Integration & Parameters

Moxifloxacin (SKU B1218, APExBIO) is supplied as a stable solid for research use. Recommended storage is at -20°C to preserve compound integrity. For in vitro studies, dissolve in water, DMSO, or ethanol to required concentrations, ensuring dissolution with gentle warming and sonication. Standard working concentrations for cytotoxicity and proliferation assays in RGC5 cells range from 10 to 100 μg/mL; significant effects are typically observed above 50 μg/mL (mechanistic analysis). For animal studies, intravenous dosages between 75 mg/kg (no metabolic effect) and 100 mg/kg (metabolic changes) are reported. Proper controls are essential to distinguish direct antibacterial effects from secondary metabolic responses. Researchers are advised to reference the APExBIO Moxifloxacin product page for detailed preparation and safety guidelines.

Conclusion & Outlook

Moxifloxacin remains a benchmark compound for studying DNA gyrase inhibition, antibiotic toxicity, and cellular stress responses. Its well-characterized mechanism and validated performance in both bacterial and mammalian systems make it a valuable tool for translational research. Future studies may further clarify its immunological effects and resistance profiles. APExBIO’s high-quality Moxifloxacin (SKU B1218) supports reproducible and scalable research into antibacterial mechanisms and metabolic regulation.